ADMA Biologics (NASDAQ:ADMA) Trading Down 3.2%

ADMA Biologics, Inc. (NASDAQ:ADMA)’s stock price was down 3.2% during mid-day trading on Tuesday . The stock traded as low as $19.30 and last traded at $19.39. Approximately 601,865 shares traded hands during trading, a decline of 83% from the average daily volume of 3,458,099 shares. The stock had previously closed at $20.03.

Wall Street Analysts Forecast Growth

ADMA has been the topic of a number of research analyst reports. Mizuho increased their target price on ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, June 20th. HC Wainwright raised their price target on shares of ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a research report on Friday. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $15.50.

ADMA Biologics Stock Performance

The firm has a 50 day simple moving average of $15.90 and a 200-day simple moving average of $11.10. The company has a market cap of $4.44 billion, a price-to-earnings ratio of -1,001.50 and a beta of 0.61. The company has a debt-to-equity ratio of 0.74, a current ratio of 6.87 and a quick ratio of 2.80.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. The firm had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The business’s revenue was up 78.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.02) EPS. As a group, analysts predict that ADMA Biologics, Inc. will post 0.49 EPS for the current fiscal year.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Young Kwon sold 60,000 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total value of $1,095,600.00. Following the transaction, the director now directly owns 241,441 shares of the company’s stock, valued at approximately $4,408,712.66. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $16.90, for a total value of $408,135.00. Following the completion of the transaction, the chief operating officer now owns 449,088 shares of the company’s stock, valued at approximately $7,589,587.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Young Kwon sold 60,000 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the transaction, the director now directly owns 241,441 shares in the company, valued at $4,408,712.66. The disclosure for this sale can be found here. Insiders sold 466,900 shares of company stock worth $8,224,121 in the last 90 days. 3.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On ADMA Biologics

Institutional investors have recently bought and sold shares of the business. Quest Partners LLC bought a new stake in shares of ADMA Biologics in the second quarter worth about $29,000. EntryPoint Capital LLC bought a new position in ADMA Biologics in the first quarter valued at approximately $31,000. CWM LLC boosted its holdings in shares of ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after buying an additional 4,367 shares during the period. Acadian Asset Management LLC bought a new stake in shares of ADMA Biologics during the second quarter worth $93,000. Finally, Viewpoint Capital Management LLC raised its holdings in shares of ADMA Biologics by 18.6% during the first quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 2,416 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.